We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Potential Vaccine Prevents Chronic Urinary Tract Infections

By LabMedica International staff writers
Posted on 04 Oct 2016
A team of molecular microbiologists has developed a potential vaccine to prevent acute Escherichia coli urinary tract infections (UTIs) from becoming chronic.

About 80% of UTIs are caused by uropathogenic E. More...
coli (UPEC). Acute UTIs are characterized by frequent painful urination and abdominal or back pain and typically are treated with antibiotics. Chronic infections allow a pool of bacteria to survive in the bladder and possibly spread to the kidneys or the bloodstream, where they can cause severe disease.


UPEC express CUP pili, which are extracellular fibers tipped with adhesion proteins that bind mucosal surfaces of the urinary tract. Type 1 pili are necessary in the early stages of infection, while a second pilus, called Fml, is encoded by genes similar to those responsible for the type 1 pilus but whose function has not been known.

Investigators at Washington University School of Medicine (St. Louis, MO, USA) genetically engineered a strain of E.coli to lack the gene for the FmlH protein, which is located at the tip of Fml pili and enable the pili to attach to the bladder.

The investigators reported in the September 22, 2016, online edition of the journal Cell Host & Microbe that deletion of FmlH had no effect on UPEC virulence in an acute mouse model of cystitis. However, FmlH provided a fitness advantage during chronic cystitis, which was manifested as persistent bacteriuria, high bladder bacterial burdens, and chronic inflammation. In situ binding confirmed that FmlH bound avidly to the inflamed, but not the naive bladder.

Overall, E. coli lacking FmlH were less likely to establish chronic infections in mice than bacteria with the intact protein. In the initial phase of acute infection, the two strains multiplied to similar levels. However, by the end of the fourth week, the bacteria without FmlH were 1,000 times less numerous in the bladder and 100 times less numerous in the kidneys than the bacteria with the protein.

Vaccination with purified FmlH protein significantly protected mice from developing chronic cystitis following infection with the wild type E. coli.

“Our findings reveal how bacteria have evolved a mechanism to colonize the bladder in order to persist and cause UTIs, and our vaccination study suggests that inhibiting this mechanism could be part of a viable approach to treating or preventing these infections,” said senior author Dr. Scott Hultgren, professor of molecular microbiology at Washington University School of Medicine.

Related Links:
Washington University School of Medicine



Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.